Arrowhead Pharmaceuticals (ARWR) Competitors $19.45 -0.05 (-0.26%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARWR vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, ELAN, and BPMCShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Elanco Animal Health (ELAN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Elanco Animal Health Blueprint Medicines Qiagen (NYSE:QGEN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Does the media refer more to QGEN or ARWR? In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than Qiagen. MarketBeat recorded 20 mentions for Arrowhead Pharmaceuticals and 5 mentions for Qiagen. Arrowhead Pharmaceuticals' average media sentiment score of 0.70 beat Qiagen's score of 0.47 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor QGEN or ARWR? Arrowhead Pharmaceuticals received 295 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 65.31% of users gave Arrowhead Pharmaceuticals an outperform vote while only 60.88% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.88% Underperform Votes16039.12% Arrowhead PharmaceuticalsOutperform Votes54465.31% Underperform Votes28934.69% Which has higher valuation and earnings, QGEN or ARWR? Qiagen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.18$341.30M$0.39114.54Arrowhead Pharmaceuticals$3.55M681.57-$599.49M-$5.02-3.87 Do analysts prefer QGEN or ARWR? Qiagen currently has a consensus target price of $51.88, suggesting a potential upside of 16.13%. Arrowhead Pharmaceuticals has a consensus target price of $42.70, suggesting a potential upside of 119.54%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.64 Do institutionals & insiders have more ownership in QGEN or ARWR? 70.0% of Qiagen shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, QGEN or ARWR? Qiagen has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Is QGEN or ARWR more profitable? Qiagen has a net margin of 4.73% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 13.43% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Arrowhead Pharmaceuticals N/A -182.69%-64.04% SummaryQiagen beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-3.8710.5991.3417.19Price / Sales681.57195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book12.635.104.794.78Net Income-$599.49M$151.51M$120.07M$225.60M7 Day Performance-10.98%-2.15%-1.90%-1.23%1 Month Performance6.19%-3.14%11.45%3.37%1 Year Performance-32.37%11.50%30.63%16.58% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.3641 of 5 stars$19.45-0.3%$42.70+119.5%-30.1%$2.42B$3.55M-3.87400Analyst ForecastInsider TradeHigh Trading VolumeQGENQiagen3.7415 of 5 stars$45.62+0.5%$51.15+12.1%+3.1%$10.41B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0406 of 5 stars$83.69+0.8%$97.23+16.2%+27.8%$8.87B$612.78M-95.91560ROIVRoivant Sciences3.0418 of 5 stars$12.04+1.7%$17.93+48.9%+16.2%$8.76B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.128 of 5 stars$136.11+4.8%$191.77+40.9%+12.6%$8.25B$327.43M-16.52640RVMDRevolution Medicines4.5467 of 5 stars$46.00+2.2%$63.67+38.4%+71.5%$7.74B$11.58M-12.54443Insider TradeLNTHLantheus4.3768 of 5 stars$93.80+0.8%$130.00+38.6%+53.4%$6.52B$1.50B15.42834Analyst ForecastLEGNLegend Biotech1.553 of 5 stars$34.26-2.4%$81.54+138.0%-43.2%$6.26B$520.18M-36.971,800NUVLNuvalent2.1736 of 5 stars$86.78-0.1%$112.60+29.8%+16.9%$6.17BN/A-25.0340Insider TradeNews CoveragePositive NewsELANElanco Animal Health3.7675 of 5 stars$12.17+0.6%$16.75+37.6%-17.0%$6.02B$4.45B30.259,300BPMCBlueprint Medicines2.5942 of 5 stars$94.27+1.2%$122.11+29.5%+7.2%$5.99B$249.38M-44.17640Insider Trade Related Companies and Tools Related Companies Qiagen Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Legend Biotech Alternatives Nuvalent Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARWR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
